Published in Lancet on January 25, 2003
Autophagy of mitochondria: a promising therapeutic target for neurodegenerative disease. Cell Biochem Biophys (2014) 0.82
Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol (2011) 25.66
Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria". Ann Neurol (2005) 24.22
Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med (2010) 13.82
A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med (2006) 11.29
Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med (2012) 7.58
Meta-analysis of genome scans and replication identify CD6, IRF8 and TNFRSF1A as new multiple sclerosis susceptibility loci. Nat Genet (2009) 7.16
Randomized trial of oral teriflunomide for relapsing multiple sclerosis. N Engl J Med (2011) 4.93
Steroid-responsive encephalopathy associated with autoimmune thyroiditis. Arch Neurol (2006) 4.25
Genome-wide association analysis of susceptibility and clinical phenotype in multiple sclerosis. Hum Mol Genet (2008) 3.93
Pathway and network-based analysis of genome-wide association studies in multiple sclerosis. Hum Mol Genet (2009) 3.92
Genome-wide meta-analysis identifies novel multiple sclerosis susceptibility loci. Ann Neurol (2011) 3.52
The natural history of multiple sclerosis: a geographically based study 10: relapses and long-term disability. Brain (2010) 3.48
250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study. Lancet Neurol (2009) 3.37
MS disease activity in RESTORE: a randomized 24-week natalizumab treatment interruption study. Neurology (2014) 3.27
Placebo-controlled trial of oral laquinimod for multiple sclerosis. N Engl J Med (2012) 3.16
Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study. Lancet Neurol (2011) 3.16
Relapse and disability outcomes in patients with multiple sclerosis treated with fingolimod: subgroup analyses of the double-blind, randomised, placebo-controlled FREEDOMS study. Lancet Neurol (2012) 2.68
Evidence for acute neurotoxicity after chemotherapy. Ann Neurol (2010) 2.45
Pregnancy outcomes in the clinical development program of fingolimod in multiple sclerosis. Neurology (2014) 2.41
Grey matter volume in a large cohort of MS patients: relation to MRI parameters and disability. Mult Scler (2011) 2.07
Lack of association between antimyelin antibodies and progression to multiple sclerosis. N Engl J Med (2007) 2.06
Genome-wide association study in a high-risk isolate for multiple sclerosis reveals associated variants in STAT3 gene. Am J Hum Genet (2010) 1.89
Health-related quality of life in multiple sclerosis: effects of natalizumab. Ann Neurol (2007) 1.88
Natalizumab alters transcriptional expression profiles of blood cell subpopulations of multiple sclerosis patients. J Neuroimmunol (2008) 1.85
Comparison of two dosing frequencies of subcutaneous interferon beta-1a in patients with a first clinical demyelinating event suggestive of multiple sclerosis (REFLEX): a phase 3 randomised controlled trial. Lancet Neurol (2011) 1.79
Siponimod for patients with relapsing-remitting multiple sclerosis (BOLD): an adaptive, dose-ranging, randomised, phase 2 study. Lancet Neurol (2013) 1.76
Copeptin: a novel, independent prognostic marker in patients with ischemic stroke. Ann Neurol (2009) 1.73
Onset of secondary progressive phase and long-term evolution of multiple sclerosis. J Neurol Neurosurg Psychiatry (2013) 1.69
Neutralizing antibodies to interferon beta-1b multiple sclerosis: a clinico-radiographic paradox in the BEYOND trial. Mult Scler (2011) 1.57
Midregional pro-atrial natriuretic peptide and outcome in patients with acute ischemic stroke. J Am Coll Cardiol (2010) 1.55
Combined evoked potentials as markers and predictors of disability in early multiple sclerosis. Clin Neurophysiol (2011) 1.51
Age-dependent B cell autoimmunity to a myelin surface antigen in pediatric multiple sclerosis. J Immunol (2009) 1.50
Assessment of cardiac safety during fingolimod treatment initiation in a real-world relapsing multiple sclerosis population: a phase 3b, open-label study. J Neurol (2013) 1.47
The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL. J Neurol (2009) 1.46
Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab. Mult Scler (2012) 1.46
Spatiotemporal distribution of white matter lesions in relapsing-remitting and secondary progressive multiple sclerosis. Mult Scler (2012) 1.45
Altered expression of miR-17-5p in CD4+ lymphocytes of relapsing-remitting multiple sclerosis patients. Eur J Immunol (2010) 1.44
Secondary progressive multiple sclerosis: current knowledge and future challenges. Lancet Neurol (2006) 1.40
Microarray-based classification and clinical predictors: on combined classifiers and additional predictive value. Bioinformatics (2008) 1.39
Clinical implications of benign multiple sclerosis: a 20-year population-based follow-up study. Ann Neurol (2004) 1.36
Increased neurofilament light chain blood levels in neurodegenerative neurological diseases. PLoS One (2013) 1.32
Natalizumab: targeting alpha4-integrins in multiple sclerosis. Neurodegener Dis (2008) 1.31
Anorectal malignant melanoma: extensive 45-year review and proposal for a novel staging classification. J Am Coll Surg (2013) 1.29
Impact of fingolimod therapy on magnetic resonance imaging outcomes in patients with multiple sclerosis. Arch Neurol (2012) 1.27
Teriflunomide versus subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis: a randomised, controlled phase 3 trial. Mult Scler (2013) 1.25
T-cell response against varicella-zoster virus in fingolimod-treated MS patients. Neurology (2013) 1.22
Measuring disability in relapsing-remitting MS. Neurology (2010) 1.22
Endonasal surgery for contact point headaches: a 10-year longitudinal study. Laryngoscope (2003) 1.22
Impact of exposure to interferon beta-1a on outcomes in patients with relapsing-remitting multiple sclerosis: exploratory analyses from the PRISMS long-term follow-up study. Ther Adv Neurol Disord (2011) 1.17
Monthly intravenous methylprednisolone in relapsing-remitting multiple sclerosis - reduction of enhancing lesions, T2 lesion volume and plasma prolactin concentrations. BMC Neurol (2006) 1.17
Prognostic value of copeptin: one-year outcome in patients with acute stroke. Stroke (2010) 1.17
Clinical efficacy of BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: subgroup analyses of the DEFINE study. J Neurol (2013) 1.17
Antigen-specific adaptive immune responses in fingolimod-treated multiple sclerosis patients. Ann Neurol (2011) 1.15
Extraocular blood flow and endothelin-1 plasma levels in patients with multiple sclerosis. Eur Neurol (2003) 1.11
A comparative study of CSF neurofilament light and heavy chain protein in MS. Mult Scler (2013) 1.09
Association between walking speed and age in healthy, free-living individuals using mobile accelerometry--a cross-sectional study. PLoS One (2011) 1.06
Modeling the cumulative genetic risk for multiple sclerosis from genome-wide association data. Genome Med (2011) 1.06
The Diagnostic and Prognostic Role of microRNA in Colorectal Cancer - a Comprehensive review. J Cancer (2013) 1.05
A highly sensitive electrochemiluminescence immunoassay for the neurofilament heavy chain protein. J Neuroimmunol (2010) 1.05
Altered microRNA expression in B lymphocytes in multiple sclerosis: towards a better understanding of treatment effects. Clin Immunol (2012) 1.04
MRI monitoring of immunomodulation in relapse-onset multiple sclerosis trials. Nat Rev Neurol (2011) 1.03
Mannose-binding lectin deficiency is associated with smaller infarction size and favorable outcome in ischemic stroke patients. PLoS One (2011) 1.03
Magnetic resonance imaging outcomes from a phase III trial of teriflunomide. Mult Scler (2013) 1.03
Evidence-based guidelines: MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis-establishing disease prognosis and monitoring patients. Nat Rev Neurol (2015) 1.03
Relevance of spinal cord abnormalities to clinical disability in multiple sclerosis: MR imaging findings in a large cohort of patients. Radiology (2013) 1.03
Magnetic resonance imaging effects of interferon beta-1b in the BENEFIT study: integrated 2-year results. Arch Neurol (2007) 1.01
Working memory training in patients with multiple sclerosis - comparison of two different training schedules. Restor Neurol Neurosci (2009) 0.99
Contribution of cortical and white matter lesions to cognitive impairment in multiple sclerosis. Mult Scler (2013) 0.99
Rapamycin attenuates the progression of tau pathology in P301S tau transgenic mice. PLoS One (2013) 0.98
Association of regional gray matter volume loss and progression of white matter lesions in multiple sclerosis - A longitudinal voxel-based morphometry study. Neuroimage (2008) 0.98
Effects of delayed-release dimethyl fumarate on MRI measures in the Phase 3 DEFINE study. J Neurol (2014) 0.97
Multiple sclerosis as a generalized CNS disease--comparative microarray analysis of normal appearing white matter and lesions in secondary progressive MS. J Neuroimmunol (2004) 0.97
Multivariate pattern classification of gray matter pathology in multiple sclerosis. Neuroimage (2012) 0.96
Subgroups of the BENEFIT study: risk of developing MS and treatment effect of interferon beta-1b. J Neurol (2007) 0.96
European validation of a standardized clinical description of multiple sclerosis. J Neurol (2004) 0.96
Additional efficacy endpoints from pivotal natalizumab trials in relapsing-remitting MS. J Neurol (2011) 0.95
Serum-based DNA methylation biomarkers in colorectal cancer: potential for screening and early detection. J Cancer (2013) 0.93
Learning from nature: pregnancy changes the expression of inflammation-related genes in patients with multiple sclerosis. PLoS One (2010) 0.92
Immune-mediated neuropathies: etiology and pathogenic relationship to aging processes. J Neuroimmunol (2003) 0.92
Accuracy of the actibelt(®) accelerometer for measuring walking speed in a controlled environment among persons with multiple sclerosis. Gait Posture (2011) 0.92
Effect of immunomodulatory medication on regional gray matter loss in relapsing-remitting multiple sclerosis--a longitudinal MRI study. Brain Res (2010) 0.92
Effects of interferon beta-1b on cognitive performance in patients with a first event suggestive of multiple sclerosis. Mult Scler (2012) 0.91
Development and validation of a new method to measure walking speed in free-living environments using the actibelt® platform. PLoS One (2011) 0.91
Abnormal connectivity of the sensorimotor network in patients with MS: a multicenter fMRI study. Hum Brain Mapp (2009) 0.91
Analysis of impairment related functional architecture in MS patients during performance of different attention tasks. J Neurol (2003) 0.91
The relationship between total and regional corpus callosum atrophy, cognitive impairment and fatigue in multiple sclerosis patients. Mult Scler (2013) 0.91
Oculopharyngeal muscular dystrophy - an under-diagnosed disorder? Swiss Med Wkly (2005) 0.90
Mental health problems in children of somatically ill parents, e.g. multiple sclerosis. Eur Child Adolesc Psychiatry (2006) 0.90
Pre-specified subgroup analyses of a placebo-controlled phase III trial (TEMSO) of oral teriflunomide in relapsing multiple sclerosis. Mult Scler (2012) 0.89
Longitudinal gray matter changes in multiple sclerosis--differential scanner and overall disease-related effects. Hum Brain Mapp (2011) 0.89
Neutralising antibodies to interferon beta in multiple sclerosis : expert panel report. J Neurol (2007) 0.89
Atorvastatin added to interferon β for relapsing multiple sclerosis: a randomized controlled trial. J Neurol (2012) 0.89
Spatiotemporal distribution pattern of white matter lesion volumes and their association with regional grey matter volume reductions in relapsing-remitting multiple sclerosis. Hum Brain Mapp (2010) 0.88
Discrepancies in the interpretation of clinical symptoms and signs in the diagnosis of multiple sclerosis. A proposal for standardization. Mult Scler (2005) 0.88
Anti-interferon-beta neutralising activity is not entirely mediated by antibodies. J Neuroimmunol (2007) 0.88
Dimethyl fumarate for multiple sclerosis. Expert Opin Investig Drugs (2010) 0.88
Altered functional adaptation to attention and working memory tasks with increasing complexity in relapsing-remitting multiple sclerosis patients. Hum Brain Mapp (2010) 0.88
Teriflunomide reduces relapse-related neurological sequelae, hospitalizations and steroid use. J Neurol (2013) 0.87
Natalizumab therapy for multiple sclerosis. Semin Neurol (2013) 0.87
Magnetic resonance imaging predictors of conversion to multiple sclerosis in the BENEFIT study. Arch Neurol (2009) 0.86